SCHEMBL19969339

SCHEMBL19969339

CN(C(=O)C(Cc1cc(F)cc(F)c1)NS(=O)(=O)N[C@@H](Cc1cc(F)cc(F)c1)C(=O)N(C)c1ccc2scnc2c1)c1ccc2scnc2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
PDE10A Q9Y233 4/20 0.33
CA12 O43570 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
FFAR1 O14842 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD11B1 P28845 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
TRPV3 Q8NET8 1/20 0.31
DYRK2 Q92630 1/20 0.31
KDR P35968 1/20 0.31
USP9X Q93008 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19962082 1.00 SYK (0.34) SYKALOX5APFEN1PDE10ACA12
SCHEMBL19962152 0.92 PDE10A (0.34) SYKALOX5APFEN1PDE10AFFAR1
SCHEMBL18180271 0.92 SYK (0.31) SYKALOX5APFEN1PDE10A
SCHEMBL19969198 0.92 SYK (0.31) SYKALOX5APFEN1PDE10A
SCHEMBL19969220 0.88 PDE10A (0.34) SYKPDE10AFFAR1HSD11B1NPC1
SCHEMBL16670170 0.87 FFAR1 (0.34) SYKPDE10AFFAR1HSD11B1NPC1
SCHEMBL19969161 0.87 PDE10A (0.31) PDE10ATAS1R3TAS1R1
SCHEMBL18181428 0.87 SYK (0.30) SYK
SCHEMBL18180300 0.86 NOS2 (0.36) SYKPDE10AFFAR1HSD11B1NPC1
SCHEMBL19962010 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E SYK 3583/4885ALOX5AP 3812/4885FEN1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.